1789-09-9

Basic information

• Product Name: 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-methyl-
• CAS NO: 1789-09-9
• Molecular Formula: C15H12N2O2
• Molecular Weight: 252.272
• Mol File: 1789-09-9.mol
• Article Data: 12

Chemical Properties

• CAS DataBase Reference: 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-methyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-methyl-(1789-09-9)
• EPA Substance Registry System: 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-methyl-(1789-09-9)

Safety Data

• Hazardous Substances Data: 1789-09-9(Hazardous Substances Data)

Upstream product

• 30507-16-5 3-(4-methoxyphenyl)-2-methylquinazolin-4(3H)-one 
• 525-76-8 2-methyl-4-oxo-3,1-benzoxazine 
• 123-30-8 4-amino-phenol 
• 1445-45-0 Trimethyl orthoacetate 
• 100-02-7 4-nitro-phenol 
• 610-14-0 2-nitrobenzyl chloride 
• 89-52-1 o-acetylamino-benzoic acid 
• 118-92-3 anthranilic acid 
• 1885-29-6 anthranilic acid nitrile 
• 25116-00-1 2-acetamidobenzonitrile 

Downstream Products

• 127780-51-2 3-<4-(2,3-epoxypropoxy)phenyl>-2-methyl-4(3H)quinazolone 
• 1214739-93-1 (S)-1-(5-methoxy-4-(3-(4-(2-methyl-4-oxoquinazolin-3(4H)-yl)phenoxy)propoxy)-2-nitrobenzoyl)pyrrolidine-2-carbaldehyde diethyl dithioacetal 
• 1214739-75-9 3-(4-(3-bromopropoxy)phenyl)-2-methylquinazolin-4(3H)-one 
• 1214739-77-1 3-(4-(5-bromopentyloxy)phenyl)-2-methylquinazolin-4(3H)-one 
• 1214739-76-0 3-(4-(4-bromobutoxy)phenyl)-2-methylquinazolin-4(3H)-one 
• 1073340-46-1 3-(4-[(1-tert-butoxycarbonyl-3-pyrrolidinyl)oxy]phenyl)-2-methyl-4(3H)-quinazolinone 
• 1073341-12-4 3-(4-[(1-tert-butoxycarbonyl-4-azepanyl)oxy]phenyl)-2-methyl-4(3H)-quinazolinone 
• 1044749-56-5 3-{4-[(3-chloropropyl)oxy]phenyl}-2-methyl-4-(3H)-quinazolinone 
• 862310-10-9 3-(4-[(1-tert-butoxycarbonyl-4-piperidinyl)oxy]phenyl)-2-methyl-4(3H)-quinazolinone 
• 862311-15-7 3-(4-[(3-hydroxycyclopentyl)oxy]phenyl)-2-methyl-4(3H)-quinazolinone 
• 862310-92-7 2-methyl-3-(4-[(4-oxocyclohexyl)oxy]phenyl)-4(3H)-quinazolinone 
• 127780-55-6 3-(4-{3-[4-(4-Bromo-phenyl)-piperazin-1-yl]-2-hydroxy-propoxy}-phenyl)-2-methyl-3H-quinazolin-4-one 
• 127780-54-5 3-{4-[2-Hydroxy-3-(4-o-tolyl-piperazin-1-yl)-propoxy]-phenyl}-2-methyl-3H-quinazolin-4-one 
• 127780-52-3 2-methyl-3-<4-<3-(4-phenyl-1-piperazinyl)-isopropanoloxy>-phenyl>-4(3H) quinazolone 

Relevant articles and documents

Synthesis of new 3-phenylquinazolin-4(3H)-one derivatives as potent antibacterial agents effective against methicillin- and vancomycin-resistant Staphylococcus aureus (MRSA and VRSA)

Occurrence of infections due to the drug resistant Staphylococcus aureus is on rise necessitating the need for rapid development of new antibacterial agents. In our present work, a series of new 3-phenylquinazolin-4(3H)-one derivatives were designed, synthesized and evaluated for their antibacterial activity against ESKAP (E. coli, S. aureus, K. pneumoniae, A. baumannii, P. aeroginosa) pathogen panel and pathogenic mycobacterial strains. The study revealed that compounds 4a, 4c, 4e, 4f, 4g, 4i, 4o and 4p exhibited selective and potent inhibitory activity against Staphylococcus aureus with MIC values in the range of 0.125–8 μg/mL. Further, the compounds 4c, 4e and 4g were found to be non toxic to Vero cells (CC50 = >10–>100 μg/mL) and exhibited favourable selectivity index (SI = 40–>200). The compounds 4c, 4e and 4g also showed potent inhibitory activity against various MDR-S. aureus including VRSA. The promising results obtained indicated the potential use of the above series of compounds as promising antibacterial agents for the treatment of multidrug resistant Staphylococcus aureus infections.

Design, synthesis and in vivo screening of some novel quinazoline analogs as anti-hyperlipidemic and hypoglycemic agents

A novel series of substituted quinazoline derivatives were designed, synthesized and evaluated for their hypolipidemic activity in cholesterol induced hyperlipidemic rats. In vivo screening concluded that compounds A-4, C-5 and C-6 have shown potent antihyperlipidemic activity by decreasing the plasma level of triglycerides (TG), very low density lipoprotein (VLDL), low density lipoprotein (LDL), followed by increase in level of high density lipoprotein (HDL).

The reaction of 2-(acylamino)benzonitriles with primary aromatic amines: A convenient synthesis of 2-substituted 4-(arylamino)quinazolines

Abstract 2-Substituted 4-(arylamino)quinazolines were prepared from 2-(acylamino)benzonitriles and primary arylamines by refluxing in either ethanol using trifluoroacetic acid as a catalyst or acetic acid. The 2-aminobenzonitrile was acylated by reaction with anhydrides, isocyanates, or ethyl chloroformate at room temperature.